BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36836195)

  • 1. Determination of Whether Apex or Non-Apex Prostate Cancer Is the Best Candidate for the Use of Prostate-Specific Antigen Density to Predict Pathological Grade Group Upgrading and Upstaging after Radical Prostatectomy.
    Huang C; He S; He Q; Gong Y; Song G; Zhou L
    J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36836195
    [No Abstract]   [Full Text] [Related]  

  • 2. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
    Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
    BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prevalence and risk factors of upgrading of Gleason grade group between transrectal ultrasound prostate biopsy and prostatectomy specimens.
    Promsen W; Siriboonrid S; Binsri N; Kanjanatarayon S; Wiriyabanditkul W; Jiraanankul V
    Urol Ann; 2023; 15(1):18-21. PubMed ID: 37006215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined multiple clinical characteristics for prediction of discordance in grade and stage in prostate cancer patients undergoing systematic biopsy and radical prostatectomy.
    Liu H; Tang K; Xia D; Peng E; Wang L; Chen Z
    Pathol Res Pract; 2020 Nov; 216(11):153235. PubMed ID: 33035728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple Tissue Biomarkers Independently and Additively Predict Prostate Cancer Pathology Outcomes.
    Cooperberg MR; Cowan JE; Lindquist KJ; Kobayashi Y; Simko JP; Bengtsson H; Singh K; Ngo V; Avila A; Newcomb LF; Tretriakova M; Lin DW; Stone S; Carroll PR; Paris PL
    Eur Urol; 2021 Jan; 79(1):141-149. PubMed ID: 33148472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological factors associated with pathological upgrading from biopsy to prostatectomy in patients with ISUP grade group ≤2 prostate cancer.
    Li X; Wang ZX; Zhu YP; Wang J; Yin YS; Zeng XY
    Asian J Androl; 2022; 24(5):487-493. PubMed ID: 35170453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiparametric Magnetic Resonance Imaging-based Prostate Specific Antigen Density and PI-RADSv2 score help identify Apical Prostate Cancer.
    Huang C; Rui R; Feng N; He Q; Gong Y; Li X; He S; Zhou L
    J Cancer; 2023; 14(8):1371-1380. PubMed ID: 37283788
    [No Abstract]   [Full Text] [Related]  

  • 9. Prostate-specific Antigen Density Is a Good Predictor of Upstaging and Upgrading, According to the New Grading System: The Keys We Are Seeking May Be Already in Our Pocket.
    Brassetti A; Lombardo R; Emiliozzi P; Cardi A; Antonio V; Antonio I; Aldo S; Tommaso R; Alberto P; Gianluca D
    Urology; 2018 Jan; 111():129-135. PubMed ID: 29032238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy.
    Keefe DT; Schieda N; El Hallani S; Breau RH; Morash C; Robertson SJ; Mai KT; Belanger EC; Flood TA
    Virchows Arch; 2015 Oct; 467(4):437-42. PubMed ID: 26229020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low serum testosterone predicts upgrading and upstaging of prostate cancer after radical prostatectomy.
    Gao Y; Jiang CY; Mao SK; Cui D; Hao KY; Zhao W; Jiang Q; Ruan Y; Xia SJ; Han BM
    Asian J Androl; 2016; 18(4):639-43. PubMed ID: 26732103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic value of
    Zheng A; Wang Z; Luo L; Chang R; Gao J; Wang B; Duan X
    Front Oncol; 2023; 13():1169189. PubMed ID: 37234988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathological upgrading and upstaging at radical prostatectomy in Jamaican men with low-risk prostate cancer.
    Morrison BF; Aiken WD; Reid G; Mayhew R; Hanchard B
    Ecancermedicalscience; 2019; 13():971. PubMed ID: 31921342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Influence of Endogenous Testosterone Density on Unfavorable Disease and Tumor Load at Final Pathology in Intermediate-Risk Prostate Cancer: Results in 338 Patients Treated with Radical Prostatectomy and Extended Pelvic Lymph Node Dissection.
    Porcaro AB; Panunzio A; Tafuri A; Cerrato C; Gallina S; Bianchi A; Rizzetto R; Amigoni N; Gozzo A; Serafin E; Cianflone F; Migliorini F; Vidiri S; Di Filippo G; Novella G; Brunelli M; Shakir A; Pagliarulo V; Cerruto MA; Siracusano S; Antonelli A
    Urol Int; 2022; 106(9):928-939. PubMed ID: 35081537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance characteristics of prostate-specific antigen density and biopsy core details to predict oncological outcome in patients with intermediate to high-risk prostate cancer underwent robot-assisted radical prostatectomy.
    Yashi M; Nukui A; Tokura Y; Takei K; Suzuki I; Sakamoto K; Yuki H; Kambara T; Betsunoh H; Abe H; Fukabori Y; Nakazato Y; Kaji Y; Kamai T
    BMC Urol; 2017 Jun; 17(1):47. PubMed ID: 28645325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of MyProstateScore (MPS) with prostate cancer grade in the radical prostatectomy specimen.
    Eyrich NW; Wei JT; Niknafs YS; Siddiqui J; Ellimoottil C; Salami SS; Palapattu GS; Mehra R; Kunju LP; Tomlins SA; Chinnaiyan AM; Morgan TM; Tosoian JJ
    Urol Oncol; 2022 Jan; 40(1):4.e1-4.e7. PubMed ID: 34753659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy.
    Nocera L; Wenzel M; Collà Ruvolo C; Würnschimmel C; Tian Z; Gandaglia G; Fossati N; Chun FKH; Mirone V; Graefen M; Saad F; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
    World J Urol; 2022 Jan; 40(1):103-110. PubMed ID: 34436637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Racial variation in prostate cancer upgrading and upstaging among men with low-risk clinical characteristics.
    Jalloh M; Myers F; Cowan JE; Carroll PR; Cooperberg MR
    Eur Urol; 2015 Mar; 67(3):451-7. PubMed ID: 24746973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upgrading and upstaging in prostate cancer: From prostate biopsy to radical prostatectomy.
    D'Elia C; Cerruto MA; Cioffi A; Novella G; Cavalleri S; Artibani W
    Mol Clin Oncol; 2014 Nov; 2(6):1145-1149. PubMed ID: 25279213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate Health Index (
    Yan JQ; Huang D; Huang JY; Ruan XH; Lin XL; Fang ZJ; Gao Y; Jiang HW; Wu YS; Na R; Xu DF
    Asian J Androl; 2022; 24(4):406-410. PubMed ID: 34782549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.